Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli
about
FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53TExploring the accessible conformations of N-terminal acetylated α-synucleinThe Synaptic Function of α-SynucleinThe Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implicationDisease-toxicant interactions in Parkinson's disease neuropathologyInsights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data.Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiologyRegulation of Weibel-Palade body exocytosis by alpha-synuclein in endothelial cells.Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons.Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways.Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease.Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease.Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease.Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Protein-misfolding diseases and chaperone-based therapeutic approaches.Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior.Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells.The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (Aβ)-associated cell death.The cellular prion protein (PrP(C)): its physiological function and role in diseaseCaspase inhibitors as neuroprotective agents.Structural changes in alpha-synuclein affect its chaperone-like activity in vitro.Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases.Direct α-synuclein promoter transactivation by the tumor suppressor p53.Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates alpha-synuclein monoubiquitylation and inclusion formation.Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease.Molecular mechanisms of alpha-synuclein neurodegeneration.Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6.Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases.Parkin: much more than a simple ubiquitin ligase.α-Synuclein in Parkinson's disease.α-Synuclein and neuronal cell death.Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.Cell Biology and Pathophysiology of α-Synuclein.Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism.PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway.Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
P2860
Q24311758-FF0CC714-D08A-4E25-A533-6377B63A6474Q26852660-F60B3F5F-AE27-4940-AA74-3FA44E8EA512Q27694711-C7DF92CE-720E-4CAE-97D6-E32933BF6E34Q28604244-02ECC1F8-0A80-4D5D-A188-02C9BEC964D5Q29248297-8CD4BE36-254C-4495-BEE4-582A1E840924Q33365370-10EDB94D-12B3-488C-90A2-F71B05237E44Q33470625-FED02BFF-B17C-4496-81EB-AC8765FC1BA0Q33603777-E92443C9-64A4-4D5A-A3B3-AA4B57B16345Q33967323-5471C022-AB05-447E-8FFC-30B7554133B1Q34021637-3A2166E3-B7D2-477B-9CEA-14C5AA888137Q34139335-78D14E0B-A573-4561-A6B8-9805FA0D1D5BQ34189618-E593051E-F199-44D1-9B19-24B847DFC56EQ34214842-2D8010F8-F433-4C0C-83D2-C91BD3E34160Q34336792-09B5CCC5-4A8E-4064-8D50-E25EC48FB317Q34460675-4A7B11A2-A847-4E53-9D45-801802C1A586Q34524526-7E385143-B6C4-4EF5-8CEB-7A474EE5E665Q34711201-896F0E8D-E5CC-4A2B-A020-3621DC173552Q34994293-68E8FD6A-D492-4F7B-A57A-99E9D4E6653FQ35492403-24638A00-34B6-49E4-BDCD-6BD238AA75EEQ35552497-B03BB059-64EA-4B5E-B86C-6794F98A47C2Q35763065-7F64E901-65B8-4BDC-82AE-87AD6C5C1A6DQ36003019-B82A1B27-2B94-450E-8384-3B436BC5D871Q36179653-48E33B6B-C27A-43FA-A2CB-5AA739E55CCFQ36281848-2DF761F6-3B3F-46AC-9389-A00C44589419Q36329972-BB03613A-4D6D-4FC5-A891-5CD56E8954DBQ36531366-0B6D6F59-C5E1-40A9-A35C-56EF89904159Q37160968-8D5A99EA-4C28-4819-A340-2609613250A0Q37257402-20B73455-A18C-4D1B-9693-8A43B66E41BAQ37309838-A4BEDC42-F80A-46FD-B12F-150B2157ECA1Q37485355-28D95331-C0D4-45C1-A3CF-56D99008D86DQ37922607-722816B9-87A5-49D7-A636-0BAD48D6F872Q37972057-395A702E-F27B-42AF-BFBB-C7409681B751Q37987146-A9B8465C-4257-4787-9CB7-E7C9C7FE5B7CQ38039369-80596B6A-B191-4E5A-A54C-F135C96B8268Q38149753-8223E43E-0DD5-4084-AE17-3099C6BA79ABQ38659590-FE60B30F-E9B7-408B-86E9-0442B3264BD8Q39097048-56EEF8DF-B3DF-41D4-BD60-B3B2A13691A6Q39297100-715F8517-0238-4F72-B621-FA79FDB54DBAQ39418832-B6EDDF7A-7569-42C8-A2D9-A186E024E9BEQ39986517-71441118-9972-46E2-B57F-784069CA16F8
P2860
Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@ast
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@en
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@nl
type
label
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@ast
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@en
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@nl
altLabel
Wild-type but Not Parkinson's ...... l Cells from Apoptotic Stimuli
@en
prefLabel
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@ast
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@en
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@nl
P2093
P921
P3181
P356
P1476
Wild-type but not Parkinson's ...... l cells from apoptotic stimuli
@en
P2093
C A da Costa
P304
P3181
P356
10.1074/JBC.M002413200
P407
P577
2000-08-04T00:00:00Z